Table 1 Clinical characteristics of SSc subjects

From: Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organs

A20 detection by IF (dcSSc, early, N = 8)

A20 detection by IHC (dcSSc, early, N = 6)

DREAM measured by IF (dcSSc, early, N = 10)

Age, mean ± SD

55.38 ± 11.66

Age, mean ± SD

54.33 ± 9.07

Age, mean ± SD

52.10 ± 10.86

Sex, n (% Female)

75%

Sex, n (% Female)

100%

Sex, n (% Female)

60%

  1. Subjects providing skin biopsy samples for IF and IHC. Early, <3 years from the first non-Raynaud disease manifestation, late >3 years from the first non-Raynaud disease manifestation. Controls were healthy adults (75% female; median age: 50 years; range: 26–57 years).
  2. IF immunofluorescence, IHC immunohistochemistry, dcSSc diffuse cutaneous systemic sclerosis systemic sclerosis.
Back to article page